| Literature DB >> 31359741 |
Teresa Diaz de Teran1, Elena Barbagelata2, Catia Cilloniz3,4, Antonello Nicolini5, Tommaso Perazzo6, Andreas Perren7, Sibel Ocak Serin8, Martin Scharffenberg9, Giuseppe Fiorentino10, Marco Zaccagnini11, Mohamad I Khatib12, Peter Papadakos13, Habib M Rezaul Karim14, Paolo Solidoro15, Antonio Esquinas16.
Abstract
INTRODUCTION: An ageing population and steady increase in the rates of neoplasms and chronic degenerative diseases poses a challenge for societies and their healthcare systems. Because of the recent and continued advances in therapies, such as the development and widespread use of non-invasive ventilation (NIV), survival rates have increased for these pathologies. For patients with end-stage chronic respiratory diseases, the use of NIV following the onset of acute or severe chronic respiratory failure is a valid option when intubation has been excluded. EVIDENCE ACQUISITION: The following electronic databases were searched from their inception to January 2000 to December 2017: MEDLINE, EMBASE, CINHAIL, CENTRAL (Cochrane Central register of Controlled Trials), DARE (Database of Abstracts of Reviews of Effectiveness), the Cochrane Database of Systematic Reviews, ACP Journal Club database. EVIDENCE SYNTHESIS: The available evidence strongly supports the use of NIV in patients presenting with an exacerbation of chronic obstructive pulmonary disease, as well end-stage neuromuscular disease. Few studies support the use of NIV in end-stage interstitial lung disease and in morbid obesity patients. In patients with cancer has been recommend offering NIV as palliative care to improve dyspnea.Entities:
Mesh:
Year: 2019 PMID: 31359741 DOI: 10.23736/S0026-4806.19.06273-6
Source DB: PubMed Journal: Minerva Med ISSN: 0026-4806 Impact factor: 4.806